Metamark Genetics Inc. entered into a global licensing agreement with HistoRx Inc. for its Aqua technology.
The Naples, Fla.-based firm, which has operations in Cambridge, Mass., has been developing its diagnostic assays for cancer analysis using the HistoRx protein biomarker diagnostic for several years, according to the company.
Metamark designed its MetamarkDx prognostic assays, which rely on the HistoRx technology, to evaluate the molecular profile of an individual patient’s tumor to help guide doctors to a more personalized treatment and identify the lethality of cancers in earlier stages, according to the company.
“We are delighted to be working with HistoRx and are eager to develop and validate clinical diagnostics for key biomarkers using AQUA technology, and to ultimately commercialize them for the benefit of patients around the world,” Metamark CEO Mark Straley said in prepared remarks.
The company named Stanley as its CEO in November, about one month before it signed the deal with Branford, Conn.-based HistoRx. In July, the company raised $22 million in a Series B round to support the development of technology such as the MetamarkDx assay.
In May, HistoRx won a patent for its biomarkers technology for determination methods of cancer patient prognosis. The company last week added former Abbott Laboratories (NYSE:ABT) diagnostics products division vice president Jack Davis to its board.